摘要
目的探讨茵陈蒿汤治疗肝癌的潜在机制。方法将小鼠随机分为假手术组(SOG)、模型组(MG)、高、中、低给药治疗组(HDG/MDG/LDG)。采用H22肝癌细胞建立原位移植瘤模型。UHPLC-MS/MS检测肝脏胆汁酸,16 S r DNA测序分析肠道菌群差异性并确定优势菌种。结果与SOG组相比,MG组肝重增加(P<0.001),牛磺β鼠胆酸(T-β-MCA)水平降低(P<0.001);治疗组肝重较MG组均降低(P<0.05),MDG、HDG组T-β-MCA水平增加(P<0.05);各组菌群在属水平上差异具有统计学意义,具有不同的优势菌群。结论茵陈蒿汤可能通过促进初级结合胆汁酸T-β-MCA的合成而改变优势菌种,从而发挥治疗肝癌的作用。
Objective To explore the potential mechanism of Yinchenhao decoction in the treatment of liver cancer.Methods Mice were randomly divided into sham operation group(SOG),model group(MG),high,middle and low dose groups(HDG/MDG/LDG).The orthotopic transplantation tumor model was established by using H22 hepatoma cells.The bile acid in liver was detected by UHPLC-MS/MS and the difference of intestinal flora was analyzed by 16 S r DNA sequencing and the dominant bacteria were determined.Results Compared with SOG group,the liver weight of MG group increased(P<0.001),the level of taurineβ-cholic acid decreased(P<0.001),the liver weight of treatment group decreased compared with MG group(P<0.05),and the level of T-β-MCA increased in MDG and HDG groups(P<0.05).Conclusion Yinchenhao decoction may change the dominant bacteria by promoting the synthesis of taurocholic acid,primary conjugated bile acid,and thus play a role in the treatment of liver cancer.
作者
张玉梅
朱琳
师健
张春芳
张辰龙
郭凯航
王玉洁
李鹏飞
ZHANG Yumei;ZHU Lin;SHI Jian;ZHANG Chunfang;ZHANG Chenlong;GUO Kaihang;WANG Yujie;LI Pengfei(Department of Traditional Chinese Medicine,Xiang’an Hospital of Xiamen University,Fujian Province,Xiamen 361000,China;Xiamen University,Fujian Province,Xiamen 361000,China)
出处
《光明中医》
2022年第16期2939-2942,共4页
GUANGMING JOURNAL OF CHINESE MEDICINE
基金
国家青年科学基金(No.81904119)。
关键词
癥瘕
茵陈蒿汤
肝癌
肠道菌群
胆汁酸
abdominal mass
Yinchenhao decoction
hepatocellular carcinoma
intestinal flora
bile acid
